Genmab A (GMAB) Share-based Compensation (2024 - 2026)

Genmab A has reported Share-based Compensation for 3 years, with the latest figure at $49.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 96.0% year-over-year to $49.0 million; the trailing twelve-month figure through Mar 2026 stood at $224.0 million (up 25.84% YoY), and the FY2025 full-year result was $128.0 million, up 21.9% from the prior year.
• Share-based Compensation for Q1 2026 stood at $49.0 million, down from $92.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $92.0 million in Q3 2025, with the low at $24.0 million in Q1 2024.
• Historically, Share-based Compensation has averaged $53.9 million across 3 years, with a median of $51.0 million in 2024.
• Annual changes were most pronounced in 2025 — Share-based Compensation grew 4.17% — and 2026, when it jumped 96.0%.
• Genmab A's Share-based Compensation stood at $78.0 million in 2024, then climbed by 17.95% to $92.0 million in 2025, then plunged by 46.74% to $49.0 million in 2026.
• The last three Share-based Compensation figures came in at $49.0 million (Q1 2026), $92.0 million (Q3 2025), and $58.0 million (Q2 2025), per Business Quant data.